Our executive leadership taps into an expertise in liver health and strong business acumen. SEE WHO'S WHO. Vivek Devaraj, President – U.S. and Chairman ...
Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases. View Pipeline. Ongoing ...
People also ask
What happened to Intercept Pharmaceuticals stock?
Is Intercept Pharmaceuticals a buy?
Who bought Intercept Pharmaceuticals?
What is the mission of Intercept Pharma?
Latest Filings (excluding insider transactions) · 1.01 - Entry into a Material Definitive Agreement · 2.01 - Completion of Acquisition or Disposition of Assets ...
Missing: relations | Show results with:relations
Mar 7, 2023 · Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects.
Missing: relations | Show results with:relations
Nov 8, 2023 · Executive Director of Global Investor Relations. David Ford, Chief Human Resources Officer. Dr. Mark Pruzanski M.D., Founder, Advisor and ...
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver ...
Intercept Pharmaceuticals, Inc. Annual Report on Form 10-K For the Fiscal Year Ended December 31, 2022. TABLE OF CONTENTS. . . Page. Part I. . . Item 1 ...
Intercept Pharmaceuticals Inc (US:ICPT) has 113 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission ...
A high-level overview of Intercept Pharmaceuticals, Inc. (ICPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, ...
Missing: relations | Show results with:relations
